EGM
SMMT icon

Engineers Gate Manager’s Summit Therapeutics SMMT Stock Holding History

Engineers Gate Manager’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Buy
+67,871
New +$1.2M 0.01% 1092
2025
Q3 		– Sell
-87,830
Closed -$1.87M – 2496
2025
Q2 		$1.87M Buy
+87,830
New +$2M 0.02% 769

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Engineers Gate Manager's SMMT Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 67,871 shares worth $989K. The stake represents 0.01% of the portfolio and ranks #1092 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in SMMT as recently as Q2 2025.

Engineers Gate Manager first reported a position in SMMT in Q2 2025 and has held it in 2 quarters since. The position peaked at $1.87M in Q2 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Engineers Gate Manager held 67,871 shares of Summit Therapeutics worth $989K as of Q2 2026.
  • Summit Therapeutics was a new Engineers Gate Manager position in Q2 2026.
  • Summit Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1092 holding.
  • Engineers Gate Manager first reported a position in Summit Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Engineers Gate Manager's Summit Therapeutics position peaked at $1.87M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.